ALB and triple-negative breast carcinoma: Molecular and genetic therapeutics delivered via albumin nanoparticles represent a cutting-edge approach for triple-negative breast cancer (TNBC), aiming to address the aggressive nature and therapeutic resistance of this subtype through precise gene modulation.